Area of research
Cardiology and Cardiovascular Medicine · Oncology
Research interest
Research interests include Chemotherapy-induced cardiotoxicity and mitigation, Cancer Immunotherapy and Biomarkers, Cardiac Imaging and Diagnostics, and Diabetes Treatment and Management.
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes
GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction
Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Advances in Multimodality Imaging in Cardio-Oncology
Cardiotoxicity of T-Cell Antineoplastic Therapies
Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis
Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic
Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Preparing the Cardiovascular Workforce to Care for Oncology Patients
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Ibrutinib-Associated Atrial Fibrillation